Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases

Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases

Objectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for dia...

Full description

Bibliographic Details
Main Authors: Sonja Daerr, Matthias Brendel, Christian Zach, Erik Mille, Dorothee Schilling, Mathias Johannes Zacherl, Katharina Bürger, Adrian Danek, Oliver Pogarell, Andreas Schildan, Marianne Patt, Henryk Barthel, Osama Sabri, Peter Bartenstein, Axel Rominger
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:NeuroImage: Clinical
Subjects:
Alzheimer's disease
ß-amyloid
[18F]-florbetaben PET
FDG Pet
Metabolism
Perfusion
Online Access:http://www.sciencedirect.com/science/article/pii/S2213158216301863

Internet

http://www.sciencedirect.com/science/article/pii/S2213158216301863

Similar Items